- Tytuł:
-
Cost-Effectiveness of
Neoadjuvant Pembrolizumab plusChemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland. - Autorzy:
- Źródło:
- PharmacoEconomics - Open. Jan2024, Vol. 8 Issue 1, p91-101. 11p.
Czasopismo naukowe